Want to see IN:LASA full AI Analyst Report?
Top Page
Lasa Supergenerics Ltd.
(LASA)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹7.00
▼(-38.22% Downside)
Action:Reiterated
Date:06/01/26
The score is held down primarily by weak financial performance—sharp revenue decline, deeply negative margins, and negative operating cash flow—partly offset by manageable leverage and a moderately improving technical posture (price above short-term moving averages with positive MACD). Valuation is not supportive due to a negative P/E tied to ongoing losses.
Positive Factors
Low leverage
Sustained low debt-to-equity provides durable financial flexibility: it lowers fixed interest obligations, preserves borrowing capacity for working capital or capex, and gives management room to restructure operations or fund recovery without immediate dilution or distress financing.
Negative Factors
Severe revenue decline
A near three-quarter revenue collapse is a structural red flag: it can reflect lost contracts, market-share erosion or product obsolescence. Sustained low scale undermines margins, reduces bargaining power with suppliers, and makes fixed-cost absorption and recovery materially harder.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Sustained low debt-to-equity provides durable financial flexibility: it lowers fixed interest obligations, preserves borrowing capacity for working capital or capex, and gives management room to restructure operations or fund recovery without immediate dilution or distress financing.
Read all positive factors
Lasa Supergenerics Ltd. (LASA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹370.75M
Dividend YieldN/A
Average Volume (3M)39.13K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-82.35%
EPS Growth-130.97%
CountryIN
Employees77
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-4.31
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lasa Supergenerics Ltd. Business Overview & Revenue Model
Company Description
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to...
How the Company Makes Money
LASA makes money primarily by manufacturing and selling APIs and pharmaceutical intermediates to other companies (B2B), such as finished-dosage drug manufacturers and formulators. Revenue is generated through (i) product sales of APIs/intermediate...
Lasa Supergenerics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 251.41M | 1.42B | 1.04B | 1.30B | 1.37B |
| Gross Profit | -68.91M | 362.61M | 286.95M | -111.88M | 427.84M |
| EBITDA | -73.67M | -43.91M | -64.66M | -246.85M | 84.12M |
| Net Income | -340.90M | -147.57M | -217.31M | -386.21M | -53.31M |
Balance Sheet | |||||
| Total Assets | 665.67M | 1.02B | 1.51B | 1.64B | 2.09B |
| Cash, Cash Equivalents and Short-Term Investments | 6.97M | 7.90M | 14.96M | 21.78M | 172.17M |
| Total Debt | 97.47M | 21.27M | 220.76M | 217.70M | 201.71M |
| Total Liabilities | 169.44M | 178.19M | 541.92M | 455.69M | 512.87M |
| Stockholders Equity | 496.23M | 837.13M | 966.76M | 1.18B | 1.58B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -28.24M | 21.39M | -173.00M | 92.12M |
| Operating Cash Flow | -80.67M | -28.24M | 21.39M | -173.00M | 92.12M |
| Investing Cash Flow | 3.27M | 81.52M | -3.98M | 111.95M | -29.12M |
| Financing Cash Flow | 77.53M | -56.62M | -19.32M | -41.61M | -403.00K |
Lasa Supergenerics Ltd. Technical Analysis
Neutral
11.33
Price Trends
7.76
Negative
7.74
Negative
9.10
Negative
Market Momentum
-0.08
Negative
50.09
Neutral
47.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Neutral. The current price of 11.33 is above the 20-day moving average (MA) of 7.42, above the 50-day MA of 7.76, and above the 200-day MA of 9.10, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.09 is Neutral, neither overbought nor oversold. The STOCH value of 47.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:LASA.
Lasa Supergenerics Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹1.09B | 8.42 | ― | ― | 2.66% | -1.90% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹1.24B | 19.66 | ― | 1.62% | 2.83% | -26.18% | |
51 Neutral | ₹545.17M | 19.94 | ― | ― | -14.99% | 399.30% | |
49 Neutral | ₹370.75M | -1.72 | ― | ― | -82.35% | -130.97% | |
43 Neutral | ₹429.26M | -0.97 | ― | ― | -26.89% | -760.69% | |
39 Underperform | ₹460.17M | -1.29 | ― | ― | -35.33% | -65.64% |
* General Sector Average
IN:LASA
Lasa Supergenerics Ltd.
7.54
-5.46
-42.00%
IN:BALPHARMA
Bal Pharma Limited
77.81
-21.29
-21.48%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
34.00
-12.69
-27.18%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
27.16
-61.59
-69.40%
IN:PAR
Par Drugs and Chemicals Limited
89.62
-4.68
-4.96%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.40
0.50
10.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.